Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of enzalutamide on oxycodone pharmacokinetics in men with prostate cancer
NL-OMON23562Not yet recruiting
- Sponsor
- Deventer Ziekenhuis
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of enzalutamide and oxycodone in prostate cancer (PCa) and pain (2 arms), sponsored by Deventer Ziekenhuis. Primary endpoint: Maximum serum concentration (Cmax) of oxycodone. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
enzalutamideoxycodone
03
Conditions
prostate cancer (PCa)pain
Beyond the preview
Go deeper on NL-OMON23562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23562.